Table 2. Alteration of prescription patterns after delivery in AS according to delivery after 1:1 matching.
| Variables | Without delivery (n = 418) | With delivery (n = 418) | ORa | 95% CI | aORb | 95% CI |
|---|---|---|---|---|---|---|
| Overall | 129 (30.9) | 104 (24.9) | 0.74 | 0.54–1.01 | 0.76 | 0.56–1.05 |
| Use of new corticosteroid or increase in dose | 39 (9.3) | 47 (11.2) | 1.23 | 0.79–1.92 | 1.30 | 0.83–2.05 |
| Regular use of new NSAIDs or increase in dose | 63 (15.1) | 38 (9.1) | 0.56 | 0.36–0.88 | 0.56 | 0.36–0.87 |
| Use of new DMARDs or increase in dose | 59 (14.1) | 64 (15.3) | 1.10 | 0.76–1.60 | 1.10 | 0.75–1.61 |
| Use of TNF inhibitors | 11 (2.6) | 7 (1.7) | 0.63 | 0.24–1.66 | 0.65 | 0.24–1.72 |
Data are presented as number (%).
AS = ankylosing spondylitis, OR = odds ratio, aOR = adjusted odds ratio, CI = confidence interval, NSAIDs = non-steroid anti-inflammatory drugs, DMARDs = disease modifying anti-rheumatic drugs, TNF = tumor necrosis factor.
aOR of change in prescription patterns compared between 2 groups using a generalized linear model with binomial distribution to account for the matched nature of the data (reference group: without delivery group); bAdjusted for the presence of uveitis, inflammatory bowel disease, or psoriasis.